852291-49-7

Basic information

• Product Name: biphenyl-2-ylcarbamic acid 1-[2-(4-hydroxymethylphenylcarbamoyl)ethyl]-piperidin-4-yl ester
• Synonyms: biphenyl-2-ylcarbamic acid 1-[2-(4-hydroxymethylphenylcarbamoyl)ethyl]-piperidin-4-yl ester
• CAS NO: 852291-49-7
• Molecular Weight: 473.572
• Mol File: 852291-49-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: biphenyl-2-ylcarbamic acid 1-[2-(4-hydroxymethylphenylcarbamoyl)ethyl]-piperidin-4-yl ester(CAS DataBase Reference)
• NIST Chemistry Reference: biphenyl-2-ylcarbamic acid 1-[2-(4-hydroxymethylphenylcarbamoyl)ethyl]-piperidin-4-yl ester(852291-49-7)
• EPA Substance Registry System: biphenyl-2-ylcarbamic acid 1-[2-(4-hydroxymethylphenylcarbamoyl)ethyl]-piperidin-4-yl ester(852291-49-7)

Safety Data

• Hazardous Substances Data: 852291-49-7(Hazardous Substances Data)

Upstream product

• 131089-15-1 methyl 4-acrylamidobenzoate 
• 619-45-4 4-methoxycarbonyl aniline 
• 171723-80-1 1-benzyl-4-piperidylbiphenyl-2-ylcarbamate 
• 743460-55-1 biphenyl-2-ylcarbamic Acid 1-[2-(4-(Aminomethyl)phenylcarbamoyl)-ethyl]piperidin-4-yl Ester 
• 623-04-1 4-aminobenzenemethanol 
• 743460-36-8 3-[4-[(2-phenylphenyl)carbamoyloxy]-1-piperidyl]propanoic acid 
• 179398-51-7 N-[4-(hydroxymethyl)phenyl]prop-2-enamide 
• 171722-92-2 4-piperidyl N-(2-biphenyl)carbamate 
• 17337-13-2 [1,1'-biphenyl]-2-yl-isocyanate 
• 4727-72-4 1-benzyl-4-hydroxypiperidine 

Downstream Products

• 852291-50-0 Biphenyl-2-ylcarbamic Acid 1-[2-(4-Formylphenylcarbamoyl)-ethyl]piperidin-4-yl Ester 

Relevant articles and documents

Discovery of (R)-1-(3-((2-Chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1′-biphenyl]-2-ylcarbamate (TD-5959, GSK961081, Batefenterol): First-in-Class dual pharmacology multivalent muscarinic antagonist and β2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD)

Through application of our multivalent approach to drug discovery we previously reported the first discovery of dual pharmacology MABA bronchodilators, exemplified by 1. Herein we describe the subsequent lead optimization of both muscarinic antagonist and β2 agonist activities, through modification of the linker motif, to achieve 24 h duration of action in a guinea pig bronchoprotection model. Concomitantly we targeted high lung selectivities, low systemic exposures and identified crystalline forms suitable for inhalation devices. This article culminates with the discovery of our first clinical candidate 12f (TD-5959, GSK961081, batefenterol). In a phase 2b trial, batefenterol produced statistical and clinically significant differences compared to placebo and numerically greater improvements in the primary end point of trough FEV1 compared to salmeterol after 4 weeks of dosing in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Biphenyl compounds useful as muscarinic receptor antagonists

This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, Ar1, R1, R2, R3, R4, R6, R7, R8, and W are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

The invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7a, R7b, W, G1, G2, a, b, c, d and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.